中国肺癌杂志2024，Vol.27Issue(4)：283-290,8.DOI:10.3779/j.issn.1009-3419.2024.101.07
分子靶向治疗在EGFR突变肺鳞癌中的研究进展
Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer
熊丙万 1柯文飞 1江文洋1
作者信息
- 1. 430060 武汉,武汉大学人民医院胸外科
- 折叠
摘要
Abstract
Non-small cell lung cancer(NSCLC)is a prevalent tumour type in our country,with lung squamous car-cinoma being a commonly observed NSCLC subtype besides lung adenocarcinoma.Epidermal growth factor receptor(EGFR)is a significant driver gene in lung cancer,and EGFR mutation frequency is considerably lower in lung squamous carcinoma in comparison to lung adenocarcinoma.Although targeted therapy against EGFR has demonstrated significant advancements in lung adenocarcinoma,while progress in lung squamous carcinoma has been relatively sluggish.This paper reviews recent stud-ies on molecular targeted therapy for EGFR-mutated lung squamous carcinoma and summarises the efficacy of EGFR-tyrosine kinase inhibitors(TKIs)in treating squamous carcinoma of the lung,in order to provide a reference for treating patients with EGFR-mutated squamous carcinoma of the lung.关键词
肺肿瘤/表皮生长因子受体/分子靶向治疗/表皮生长因子受体-酪氨激酸酶抑制剂Key words
Lung neoplasms/Epidermal growth factor receptor/Targeted therapy/Epidermal growth factor recep-tor-tyrosine kinase inhibitors引用本文复制引用
熊丙万,柯文飞,江文洋..分子靶向治疗在EGFR突变肺鳞癌中的研究进展[J].中国肺癌杂志,2024,27(4):283-290,8.
